iOrganBio, an innovator in intelligent cell manufacturing, today announced the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, whose research has advanced the understanding of neurodegenerative diseases and contributed to the development of multiple therapeutic candidates. He serves as Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard’s Department of Stem Cell and Regenerative Biology.
Dr. Rubin’s pioneering work spans blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His extensive academic and entrepreneurial leadership will be key to expanding iOrganBio’s platform in neurological applications.
iOrganBio’s CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency, enabling scalable production for disease modeling, drug discovery, and cell therapy development. The company's functional human CellAtlas provides the digital blueprints for each cell type, guiding a smart, closed-loop manufacturing process.
"We are honored to welcome Dr. Rubin to our Scientific Advisory Board," said a company spokesperson. "His deep expertise in stem cell biology and neurodegenerative disease will be invaluable as we apply our CellForge platform to develop more predictive human models for neurological research and therapeutic development."
Dr. Rubin's appointment underscores iOrganBio's commitment to assembling world-class scientific leadership to drive innovation in intelligent cell manufacturing. The company's technology aims to redefine how human cells are engineered and produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs).
For more information, visit iOrgan.Bio or follow the company on LinkedIn.
